Sixty Degree Capital

Outside view of a long building with so many displays

Sixty Degree Capital Celebrates Final Close of Fund III, Raising $250M for VC Investment in High-Growth Tech Companies

By Sixty Degree Capital | November 23, 2023

November 23, 2023 – Sixty Degree Capital is excited to announce the final close of its third venture capital fund, with $250M earmarked for high-growth companies from Series A to pre-IPO stages across enterprise software and healthcare. Fund III is…

Read More

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

By Sixty Degree Capital | October 20, 2021

GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds…

Read More

Arcellx Announces Executive Appointments

By Sixty Degree Capital | October 20, 2021

Dr. Christopher Heery joins as Chief Medical Officer and Neeraj Teotia joins as Chief Commercial Officer GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new…

Read More